Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

American journal of nephrology - 1 Jan 2020

Sekine Akinari, Hoshino Junichi, Fujimaru Takuya, Suwabe Tatsuya, Mizuno Hiroki, Kawada Masahiro, Hiramatsu Rikako, Hasegawa Eiko, Yamanouchi Masayuki, Hayami Noriko, Mandai Shintaro, Chiga Motoko, Kikuchi Hiroaki, Ando Fumiaki, Mori Takayasu, Sohara Eisei, Uchida Shinichi, Sawa Naoki, Takaichi Kenmei, Ubara Yoshifumi

Abstract excerpt

BACKGROUND: Tolvaptan is the only therapeutic drug for autosomal dominant polycystic kidney disease (ADPKD). The influence of mutations in polycystic kidney disease 1 and 2 genes (PKD1 and PKD2) on the treatment effects of tolvaptan is not well documented in the literature. METHODS: We retrospectively evaluated the relationship between genotype and the efficacy of tolvaptan in 18 patients with ADPKD who had been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glomerular Filtration Rate

Share to Mutation

Share to Polycystic Kidney, Autosomal Dominant

Share to TRPP Cation Channels

Source

Identifiers

PMID: 32784291
DOI: 10.1159/000509817

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.PMID 32784291Read ↗

Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.Semantic proximity Read ↗

Genetic testing in autosomal dominant polycystic kidney disease: why it matters in 2025Semantic proximity Read ↗

PKD1 Mutation Is a Biomarker for Autosomal Dominant Polycystic Kidney Disease.Semantic proximity Read ↗

Considerations for genetic testing in individuals with autosomal dominant polycystic kidney disease.Semantic proximity Read ↗

Tolvaptan in ADPKD Beyond Trials: Tolerability, Monitoring, and Real-World OutcomesSemantic proximity Read ↗

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.Semantic proximity Read ↗

Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights.Semantic proximity Read ↗

Combining genotype with height-adjusted kidney length predicts rapid progression of ADPKD.Semantic proximity Read ↗

Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.Semantic proximity Read ↗

A Genome-Wide Association Study Identifying SVEP1 Variant as a Predictor of Response to Tolvaptan for Cirrhotic AscitesSemantic proximity Read ↗

Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease.Semantic proximity Read ↗

Perspectives on Drug Development in Autosomal Recessive Polycystic Kidney Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.